About Us

Mission & Vision

Based On The World’s first DNA Aptamer Patent, Becoming A Global Therapeutics and Healthcare Market Leader

  • DNA R&D Innovator

    Started business with R&D for the innovative DNA-based AD/PD medicines, and expand the business to healthcare and cosmeceutical markets

  • Global ingredient IPs

    World’s first perfect antioxidants DNA Aptamer, Aptamin® patents rights owner (30+)

  • Game Changer

    Go to global, and suggest new industrial standards with DNA Aptamer

Business Scope

Company History

  • 2020 ~ 2018
  • 2017 ~ 2014
  • 2020
    Aptamin®C GRAS Notification (FDA, US)
    Aptamin®C additional patent registration (US, Korea)
  • 2019
    Developed Aptamin®C ingredient for skincare
    Launched Aptamin®C finished cosmetic goods
    Posted an study results of Aptamin®C skincare on Journal of Cosmetic Dermatology
    Venture Business Certification
    TIDES, Poster Presentation
    AMWC, Poster Presentation
    InCosmetics Global, CosmeTech
    Started co-research with Kyunghee University, Chungang University, Sookmyung Women’s University
  • 2018
    Developed Aptamin®H, K, G
    Publish Aptamin®C, Aptamers
    Aptamin®C Korea Cosmetic Association Registration
    IFSCC, Poster Presentation
    IPO, Selection of an organizing company(KB securities)
  • 2017
    Aptamin®C ICID register
    Co-developed Aptamin® with Hanyang Universigy
  • 2016
    Developed Aptamin®C
    Gold prizes awarded in <Huzel Open Innovation>
  • 2015
    Developed microneedle patch type of early diagnosis system
  • 2014
    Developed contact-lens type of early diagnosis system
    Founded

Business Roadmap

Entering the global healthcare market with the start of commercializing the first DNA Aptamer in worldwide

IP(Intellectual Property)

Intellectual Property Status

2 1 7 2 7 14 8 7 PCT2 Processing
(41)
Registered
(7)
Area Applied PCT Registered Total
Aptamin® 24 2 7 33
Therapeutics 12 12
Early Diagnosis 5 5
Other
Total 41 2 7 50
  • 5
  • 7
  • 4

Osong R&D center

Build DNA R&D Center at O-song Hyper Medical Multiplex in 2021 (Total site area: 8,241.8 m²)

Executives

  • Key members
  • Advisory
  • CEO

    Wayne Lee

    ITE Co., V.President
    BizInfra Co., CEO
    IFS Korea, CEO
    IBM Korea
    Hanyang University

  • CSO

    Eric Sohn

    C.P.M / 6Sigma MBB
    G. Manager, IMaketKorea
    Samsung Fire & Marine Insurance

  • R&D Advisor

    Yoonsung Kim, M.D., Ph.D.

    Rutgers University Medical School
    Weill Cornell Medicine
    Ph.D. in Medical School, Cornell Univ.

  • R&D Advisor

    Yeongjeong Kim, Ph.D.

    Dept. of Nursing Science,
    Kyunghee University
    Post-doc. Fellowship, Weill Medical School, Cornell Univ.
    Ph.D, Kyunghee University

  • Nonexecutive Director

    Jaeryun Kwon

    CEO, Winner Study
    CEO, Korea M.N.A.
    CEO, Korea Corporate Investment Co., Ltd.

Partners & Customers

  • partner01.jpg
  • partner02.jpg
  • partner03.jpg
  • partner04.jpg
  • partner05.jpg
  • partner06.jpg
  • partner07.jpg
  • partner08.jpg
  • partner09.jpg
  • partner10.jpg
  • partner11.jpg
  • partner12.jpg
  • partner13.jpg
  • partner14.jpg
  • partner15.jpg
  • partner16.jpg
  • partner17.jpg
  • partner18.jpg
  • partner19.jpg
  • partner20.jpg
  • partner21.jpg
  • partner22.jpg
  • partner23.jpg
  • partner24.jpg
  • partner25.jpg
  • partner26.jpg
  • partner27.jpg
  • partner28.jpg